Mayo Clinic Cancer Center — Research

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. Cutaneous Lymphoma Database

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to create a  long-term, prospective database of cutaneous lymphoma that will lead to a better understanding of the biological behavior of cutaneous lymphomas as well as the effectiveness of interventions.

2. Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

   Rochester, Minn., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to find out more about the side effects of rovalpituzumab tesirine (SC16LD6.5) and what doses of rovalpituzumab tesirine (SC16LD6.5) are safe for people with specific delta-like protein 3-expressing cancers.

    

    

3. Ipilimumab, Nivolumab, and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

   Rochester, Minn.

   This phase I trial studies the side effects and best dose of ipilimumab and nivolumab when given together with brentuximab vedotin in treating patients with Hodgkin lymphoma that has returned after a period of improvement or has not responded to previous treatment. Monoclonal antibodies, such as ipilimumab and nivolumab, may interfere with the ability of cancer cells to grow and spread. Brentuximab vedotin is a combining monoclonal antibody with an anticancer drug that binds to a protein on the surface of lymphoma cells called cluster of differentiation (CD)30 and may kill the cells. Giving ipilimumab or nivolumab or both with brentuximab vedotin may kill more cancer cells.

4. Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   This is a dose escalation followed by dose expansion study of TL32711 in combination with 5-Azacitidine in subjects with Myelodysplastic syndrome who are naïve, have relapsed or have failed prior 5-azacitidine therapy. Pre-clinical and mechanistic studies support that 5-Azacitidine may modulate pathways that enable birinapant-mediated anti-tumor activity.

5. Phase II Study of EUS-guided Verteporfin PDT in Solid Pancreatic Tumors

   Rochester, Minn., Jacksonville, Fla.

   The goal of project is to target of locally advanced pancreatic cancer (LAPC) with a photodynamic therapy (PDT) to evaluate response of tumor.

6. A Study Comparing Orteronel Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer, who have not had Chemotherapy

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to evaluate orteronel (TAK-700) combined with prednisone, compared to a placebo and prednisone, for the treatment of men with progressive, metastatic, castration-resistant prostate cancer, who have not had chemotherapy.

7. A Study in Second Line Metastatic Colorectal Cancer

   Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   The purpose of this study is to compare the overall survival with ramucirumab combined with FOLFIRI or a placebo and FOLFIRI in patients who have metastatic colorectal cancer.

8. A Study of MPDL3280A (Anti-PD-L1 Antibody) Combined with Carboplatin and Paclitaxel , and with or without Bevacizumab, for Patients who have Stage IV Non-Squamous Non-Small Cell Lung Cancer

   Jacksonville, Fla.

   The purpose of this study is to evaluate the safety and effectiveness of a treatment of Atezolizumab (MPDL3280A) combined with carboplatin, paclitaxel, and with or without bevacizumab, versus carboplatin, paclitaxel and bevacizumab in patients with stage IV non-squamous non-small cell lung cancer who have never had chemo therapy.

9. Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   This phase I trial studies the side effects and best dose of cediranib maleate and selumetinib in treating patients with solid malignancies. Cediranib maleate and selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also stop the growth of tumor cells by blocking blood flow to the tumor.

10. A Study of the Quality of Life of Patients who have Hereditary Nonpolyposis Colorectal Cancer

    Rochester, Minn.

    The purpose of this study is to show the quality of life and bowel function in patients who have been diagnosed with rectal cancer and are known to have Hereditary Nonpolyposis Colorectal Cancer (HNPCC), especially to make comparisons between clinical managements, family history, and health behaviors.